Introductory Chapter: Advances in Management of AMD
Author:
Gunvant Davey Pinakin
Reference20 articles.
1. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005-2015. DOI: 10.1001/jama.2013.4997. Erratum in: JAMA. 2013 Jul 10;310(2):208. PMID: 23644932
2. Yin X, He T, Yang S, Cui H, Jiang W. Efficacy and safety of antivascular endothelial growth factor (Anti-VEGF) in treating neovascular age-related macular degeneration (AMD): A systematic review and meta-analysis. Journal of Immunology Research. 2022;2022:6004047. DOI: 10.1155/2022/6004047
3. Age-Related Eye Disease Study Research Group, Ferris FL, Davis MD, Clemons TE, Lee LY, Chew EY, et al. A simplified severity scale for age-related macular degeneration: AREDS report no. 18. Archives of Ophthalmology. 2005;123:1570-1574. DOI: 10.1001/archopht.123.11.1570
4. Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Beckman initiative for macular research classification committee. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120(4):844-851. DOI: 10.1016/j.ophtha.2012.10.036
5. Chen XD, Gardner TW. A critical review: Psychophysical assessments of diabetic retinopathy. Survey of Ophthalmology. 2021;66(2):213-230. DOI: 10.1016/j.survophthal.2020.08.003